Literature DB >> 30100006

Polycystic Ovary Syndrome.

Renate K Meier1.   

Abstract

Polycystic ovary syndrome (PCOS) is a commonly occurring endocrine disorder characterized by hirsutism, anovulation, and polycystic ovaries. Often comorbid with insulin resistance, dyslipidemia, and obesity, it also carries significant risk for the development of cardiovascular and metabolic sequelae, including diabetes and metabolic syndrome. Traditionally, the treatment of patients with PCOS has focused on relief of symptoms. Here, the criteria for the diagnosis of PCOS are reviewed with an emphasis on the stratification of subtypes by metabolic features. Then treatment options are reviewed according to the management goal: relief of hyperandrogenic symptoms, regulation of menstruation, and restoration of fertility.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anovulation; Diagnosis; Hyperandrogenism; Management; Polycystic ovary syndrome; Subtypes/phenotypes; Treatment; Women’s health

Mesh:

Year:  2018        PMID: 30100006     DOI: 10.1016/j.cnur.2018.04.008

Source DB:  PubMed          Journal:  Nurs Clin North Am        ISSN: 0029-6465            Impact factor:   1.208


  34 in total

1.  Protective effects of lidocaine on polycystic ovary syndrome through modulating ovarian granulosa cell physiology via PI3K/AKT/mTOR pathway.

Authors:  Haixia Xiong; Qiong Hu; Qun Jiang
Journal:  Cytotechnology       Date:  2022-02-24       Impact factor: 2.058

Review 2.  Efficacy and Safety of Coenzyme Q10 Supplementation in the Treatment of Polycystic Ovary Syndrome: a Systematic Review and Meta-analysis.

Authors:  Tianqing Zhang; Qi He; Hao Xiu; ZiZhu Zhang; Yao Liu; Zhenrong Chen; Hengjing Hu
Journal:  Reprod Sci       Date:  2022-08-08       Impact factor: 2.924

3.  miR-124-3p Combined with ANGPTL2 Has High Diagnostic Values for Obese and Nonobese Polycystic Ovary Syndrome.

Authors:  Hongmei Dai; Fangting Liu; Jianshu Lu; Yan Yang; Pingping Liu
Journal:  Int J Endocrinol       Date:  2022-06-14       Impact factor: 2.803

4.  Prevalence and associated risk factors for mental health problems among patients with polycystic ovary syndrome in Bangladesh: A nationwide cross-Sectional study.

Authors:  Moynul Hasan; Sumaya Sultana; Md Sohan; Shahnaj Parvin; Md Ashrafur Rahman; Md Jamal Hossain; Mohammad Saydur Rahman; Md Rabiul Islam
Journal:  PLoS One       Date:  2022-06-22       Impact factor: 3.752

5.  An update of polycystic ovary syndrome: causes and therapeutics options.

Authors:  Abeer M Rababa'h; Bayan R Matani; Alaa Yehya
Journal:  Heliyon       Date:  2022-10-10

6.  Polycystic ovary syndrome: clinical and laboratory variables related to new phenotypes using machine-learning models.

Authors:  A A Veloso; K B Gomes; I S Silva; C N Ferreira; L B X Costa; M O Sóter; L M L Carvalho; J de C Albuquerque; M F Sales; A L Candido; F M Reis
Journal:  J Endocrinol Invest       Date:  2021-09-15       Impact factor: 4.256

Review 7.  Review on bisphenol A and the risk of polycystic ovarian syndrome: an insight from endocrine and gene expression.

Authors:  Risani Mukhopadhyay; Navya B Prabhu; Shama Prasada Kabekkodu; Padmalatha S Rai
Journal:  Environ Sci Pollut Res Int       Date:  2022-02-24       Impact factor: 5.190

Review 8.  Diet and Nutrition in Gynecological Disorders: A Focus on Clinical Studies.

Authors:  Sadia Afrin; Abdelrahman AlAshqar; Malak El Sabeh; Mariko Miyashita-Ishiwata; Lauren Reschke; Joshua T Brennan; Amanda Fader; Mostafa A Borahay
Journal:  Nutrients       Date:  2021-05-21       Impact factor: 5.717

9.  The therapeutic effects of glucagon-like peptide-1 receptor agonists and metformin on polycystic ovary syndrome: A protocol for systematic review and meta-analysis.

Authors:  Ruilin Ma; Xuesong Ding; Yanfang Wang; Yan Deng; Aijun Sun
Journal:  Medicine (Baltimore)       Date:  2021-06-11       Impact factor: 1.817

Review 10.  The Potential Effect of Rhizoma coptidis on Polycystic Ovary Syndrome Based on Network Pharmacology and Molecular Docking.

Authors:  Liyun Duan; Xuedong An; Yuehong Zhang; Shenghui Zhao; Rongrong Zhou; Yingying Duan; Yuqing Zhang; Xinmin Liu; Fengmei Lian
Journal:  Evid Based Complement Alternat Med       Date:  2021-07-08       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.